Phaenopsectra profusa

NorthView Acquisition Corp Announces Filing a Registration Statement on Form S-4 in Connection with a Proposed Business Combination with Profusa, Inc.

Retrieved on: 
Wednesday, January 25, 2023

The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination Agreement between NorthView and Profusa.

Key Points: 
  • The Registration Statement contains a preliminary proxy statement/prospectus in connection with the previously announced Business Combination Agreement between NorthView and Profusa.
  • Although the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Profusa and NorthView, as well as the proposed business combination.
  • On November 7, 2022, NorthView entered into a business combination agreement with Profusa.
  • Upon completion of the proposed transaction, the combined company is expected to be listed on the Nasdaq Stock Market (“Nasdaq”).

Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger with NorthView Acquisition Corp

Retrieved on: 
Monday, November 7, 2022

Upon closing of the transaction, NorthView will be renamed Profusa Inc. (the Combined Company).

Key Points: 
  • Upon closing of the transaction, NorthView will be renamed Profusa Inc. (the Combined Company).
  • Profusa is based in Emeryville, CA and is a digital health company that is pioneering the next generation of personalized medicine via the development of novel tissue-integrated biosensors.
  • Profusas technology enables continuous transmission of wireless and cloud based actionable medical-grade data for personal, professional and medical use.
  • Profusa, aDelawarecorporation, is a digital health company that is pioneering the next generation of personalized medicine as a leading developer of novel tissue integrated biosensors.